NiKang Therapeutics and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Combination Therapies for the Treatment of Advanced Clear Cell Renal Cell Carcinoma

NiKang Therapeutics has formed a clinical trial collaboration with Pfizer (PFE) to evaluate NKT2152, targeting advanced clear cell renal cell carcinoma (ccRCC).

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Very Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

clinical trial

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/30/2021 - 08:00 AM EST

WILMINGTON, Del.--(BUSINESS WIRE)-- NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. (NYSE: PFE) to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with palbociclib, a CDK4/6 inhibitor, and sasanlimab, a subcutaneously administered PD-1 inhibitor for the treatment of advanced clear cell renal cell carcinoma (ccRCC). It will comprise two different combination regimens to treat ccRCC patients who have not responded to or relapsed from prior therapies. Under the terms of the agreement, NiKang will sponsor the study, and Pfizer will co-fund the trials and provide its drugs at no cost to NiKang. The two companies will form a Joint Development Committee to oversee this collaboration.

“We are excited to work with Pfizer, a company that has been a leader in RCC drug development for nearly two decades, and appreciate its recognition of the potential for these important combination strategies in helping ccRCC patients in need. The scientific rationale of these novel combinations is compelling as they target different and complementary pathways,” said Zhenhai Gao, Ph.D., co-founder, president, and CEO of NiKang. “This clinical collaboration provides an excellent framework under which both companies pool their proprietary products and resources together to effectively explore the potential of these combination therapies.”

NKT2152 is currently in a phase 1/2 dose escalation and expansion trial (NCT05119335). It is designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity in patients with advanced ccRCC. Once an appropriate dose is identified, combination studies including NKT2152 and Pfizer’s palbociclib and sasanlimab will commence.

About NiKang Therapeutics

NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Our target selection is driven by deep insights into disease biology and molecular pathways. Our discovery approach is informed by target structure biology and capitalizes on structure-based drug design. The successful implementation of our strategy enables us to rapidly and efficiently discover and advance proprietary drug candidates with the most desirable pharmacological features into clinical studies. We strive to bring transformative medicines to patients in need.

For more information, please visit http://www.nikangtx.com